Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.1
4.3
Journals
Pharmaceuticals
Special Issues
Pharmaceutical and Cellular Strategies to Treat GVHD
share announcement

Pharmaceutical and Cellular Strategies to Treat GVHD

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".

Deadline for manuscript submissions: closed (20 December 2021) | Viewed by 11059

Special Issue Editors

Prof. Dr. Mikhail Kiselevsky

E-Mail Website
Guest Editor
Ministry of Health of Russian Federation, Moscow, Russia
Interests: cancer immunology; stem cell biology; cancer biology; immunotherapy, bioimplants; sepsis immunopathogenesis
Dr. Lina Hsiu Kim Lim

E-Mail Website
Guest Editor
Associate Professor, Department of Physiology, NUS Immunology Program, Yong Loo Lin School of Medicine, Centre for Life Sciences, Level 3 (Immunology), #03-06J, 28 Medical Drive, Singapore
Interests: tumor microenvironment; tumor immunology; innate immunity; stress and inflammation
Prof. Svetlana Varfolomeeva

E-Mail Website
Guest Editor
Russian National Center for Oncology, Russia
Interests: pediatric oncology-hematology; high-dose chemotherapу; Graft-versus-host disease; transplantation of hematopoietic cells
Dr. Kirill Kirgizov

E-Mail Website
Guest Editor
Ministry of Health of Russian Federation, Moscow, Russia
Interests: pediatric oncology-hematology; high-dose chemotherapу; Graft-versus-host disease; transplantation of hematopoietic cells

Special Issue Information

Dear Colleagues,

Graft-versus-host disease (GVHD) is a  systemic disorder characterized by inflammation in different organs, with the specificity of epithelial cell apoptosis and crypt drop out.

Currently, intravenously administered glucocorticoids, such as prednisone, are the standard of care in acute GVHD and chronic GVHD. Other substances that have been studied for GvHD treatment include, for example: sirolimus, pentostatin, etanercept, and alemtuzumab. In August 2017 the US FDA approved ibrutinib to treat chronic GVHD after failure of other systemic treatments.

The Special Issue Pharmaceutical and Cellular Strategies to Treat GVHD will present reviews and original papers describing novel drugs and therapeutics up-to-date that hold promise for improved prevention and treatment of GVHD. The suggested papers will discuss different approaches to improve pharmaceutical strategies for prevention and treatment of GVHD (comparing methods of GVHD prevention and lymphodepletion); outline new therapeutic approaches involving innovative agents and hematopoietic stem-cell transplantation (HSCT) for pathogenetic GVHD therapy; compare the effectiveness of chemotherapy and HSCT, including promising technologies that may improve the results of treatment of patients with hematologic malignancies. Keywords: GVHD, Autoimmune Diseases, MSC, HSCT, Oncohematology, Prevention, Treatment, Chemotherapy

Prof. Mikhail Kiselevsky
Dr. Lina Hsiu Kim Lim
Prof. Svetlana Varfolomeeva
Dr. Kirill Kirgizov
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • GVHD
  • Autoimmune Diseases
  • MSC
  • HSCT
  • Oncohematology
  • Prevention
  • Treatment
  • Chemotherapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 2037 KiB  
Communication
Chondroitin Sulfate and Fucosylated Chondroitin Sulfate as Stimulators of Hematopoiesis in Cyclophosphamide-Induced Mice
by Nadezhda E. Ustyuzhanina, Natalia Yu. Anisimova, Maria I. Bilan, Fedor V. Donenko, Galina E. Morozevich, Dmitriy V. Yashunskiy, Anatolii I. Usov, Nara G. Siminyan, Kirill I. Kirgisov, Svetlana R. Varfolomeeva, Mikhail V. Kiselevskiy and Nikolay E. Nifantiev
Pharmaceuticals 2021, 14(11), 1074; https://doi.org/10.3390/ph14111074 - 24 Oct 2021
Cited by 18 | Viewed by 3054
Abstract
The immunosuppression and inhibition of hematopoiesis are considered to be reasons for the development of complications after intensive chemotherapy and allogeneic hematopoietic stem cell transplantation. Chondroitin sulfate (CS), isolated from the fish Salmo salar, and fucosylated chondroitin sulfate (FCS [...] Read more.
The immunosuppression and inhibition of hematopoiesis are considered to be reasons for the development of complications after intensive chemotherapy and allogeneic hematopoietic stem cell transplantation. Chondroitin sulfate (CS), isolated from the fish Salmo salar, and fucosylated chondroitin sulfate (FCS), isolated from the sea cucumber Apostichopus japonicus, were studied for their roles as stimulators of hematopoiesis in a model of cyclophosphamide-induced immunosuppression in mice. The recombinant protein r G-CSF was applied as a reference. The studied polysaccharides were shown to stimulate the release of white and red blood cells, as well as platelets from bone marrow in immunosuppressed mice, while r G-CSF was only responsible for the significant increase in the level of leucocytes. The analysis of different populations of leucocytes in blood indicated that r G-CSF mainly stimulated the production of neutrophils, whereas in the cases of the studied saccharides, increases in the levels of monocytes, lymphocytes and neutrophils were observed. The normalization of the level of the pro-inflammatory cytokine IL-6 in the serum and the recovery of cell populations in the spleen were observed in immunosuppressed mice following treatment with the polysaccharides. An increase in the proliferative activity of hematopoietic cells CD34(+)CD45(+) was observed following ex vivo polysaccharide exposure. Further study on related oligosaccharides regarding their potential as promising drugs in the complex prophylaxis and therapy of hematopoiesis inhibition after intensive chemotherapy and allogeneic hematopoietic stem cell transplantation seems to be warranted. Full article
(This article belongs to the Special Issue Pharmaceutical and Cellular Strategies to Treat GVHD)
►▼ Show Figures

Figure 1

11 pages, 680 KiB  
Article
Extracorporeal Photopheresis in Children with Chronic Graft-Versus-Host Disease
by Andrey Kozlov, Maria Estrina, Olesia Paina, Tatiana Bykova, Anna Osipova, Polina Kozhokar, Zhemal Rakhmanova, Irina Solodova, Elena Morozova, Alexander Alyansky, Irina Kulagina, Asmik Gevorgian, Anna Dotsenko, Ivan Moiseev, Alexey Chukhlovin, Alexander Kulagin, Sergey Bondarenko, Elena Semenova and Ludmila Zubarovskaya
Pharmaceuticals 2021, 14(8), 808; https://doi.org/10.3390/ph14080808 - 17 Aug 2021
Cited by 2 | Viewed by 3315
Abstract
Chronic graft versus host disease (cGVHD) remains a major complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). It significantly decreases survival and quality of life. The present study demonstrates retrospective data on extracorporeal photopheresis (ECP) in children with cGVHD. A total of 42 [...] Read more.
Chronic graft versus host disease (cGVHD) remains a major complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). It significantly decreases survival and quality of life. The present study demonstrates retrospective data on extracorporeal photopheresis (ECP) in children with cGVHD. A total of 42 children with steroid-refractory cGVHD were enrolled in the study. The majority of patients had acute leukemia (n = 32, 76%). All patients received ECP as second (n = 18, 43%) or third (n = 24, 57%) line of therapy. Initial ECP schedule consisted of bimonthly regimen for two consecutive days with possibility of further tapering according to response. Any concurrent treatment administered before ECP could be continued if considered necessary. Complete response to ECP was registered in seven (17%) patients and partial response in 24 (57%). Overall response according to organ involvement was as follows: skin (n = 24, 75%), mucous membranes (n = 16, 73%), liver (n = 8, 80%), gut (n = 4, 80%), lungs (n = 2, 22%) and joints (n = 2, 67%). Five-year overall, progression-free and failure-free survival was 57%, 56% and 30%, respectively. Non-relapse mortality at 5 years was 14%. We didn’t observe any clinically significant complications in children that could be attributed to the procedure. ECP remains important and safe treatment option in children with cGVHD. Full article
(This article belongs to the Special Issue Pharmaceutical and Cellular Strategies to Treat GVHD)
►▼ Show Figures

Figure 1

8 pages, 545 KiB  
Article
Relationship between CYP3A5 Polymorphism and Tacrolimus Blood Concentration Changes in Allogeneic Hematopoietic Stem Cell Transplant Recipients during Continuous Infusion
by Naoki Yoshikawa, Hidemi Takeshima, Masaaki Sekine, Keiichi Akizuki, Tomonori Hidaka, Kazuya Shimoda and Ryuji Ikeda
Pharmaceuticals 2021, 14(4), 353; https://doi.org/10.3390/ph14040353 - 10 Apr 2021
Cited by 8 | Viewed by 3614
Abstract
A polymorphism in the gene encoding the metabolic enzyme cytochrome P450 family 3 subfamily A member 5 (CYP3A5) is a particularly influential factor in the use of tacrolimus in Japanese patients. Those who are homozygotic for the *3 mutation lack CYP3A5 activity, which [...] Read more.
A polymorphism in the gene encoding the metabolic enzyme cytochrome P450 family 3 subfamily A member 5 (CYP3A5) is a particularly influential factor in the use of tacrolimus in Japanese patients. Those who are homozygotic for the *3 mutation lack CYP3A5 activity, which results in substantial individual differences in tacrolimus metabolism. The aim of this study was to analyze the relationship between individual differences in tacrolimus blood concentration changes and CYP3A5 polymorphisms in allogeneic hematopoietic stem cell transplantation recipients during the period of increasing blood concentration of the drug following treatment onset. This was a prospective observational cohort study, involving 20 patients administered tacrolimus by continuous infusion. The subjects were divided into the *1/*3 and *3/*3 groups based on CYP3A5 polymorphism analysis. The tacrolimus blood concentration/dose (C/D) ratio increased from day 1 and was largely stable on day 5, and a significant difference was observed between the *1/*3 and *3/*3 groups in the time course of the C/D ratio during this period (p < 0.05). This study reveals the effects of CYP3A5 polymorphism on continuous changes in tacrolimus blood concentration. Full article
(This article belongs to the Special Issue Pharmaceutical and Cellular Strategies to Treat GVHD)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop